New thoughts – recent data
Dr Linda PorterMCRN, West Midlands
WM-MCRN recruitment 2012/13
WM-CLRN PSG recruitment 2012/13
MCRN national performance metrics2012/13 (Q4 final draft)
A (Industry)
B (Public+CTU)
C (Public)
Target
HLO2Time and Target recruitment
80% 100% 100% 80%
HLO4Time for NHS permission
24% 80%
HLO5Time for first
patient recruited55% 25% 38% 80%
FY 2012/13 HLO2Studies closed to recruitment
WM-Central (Public) WM-Central (Industry)
WM-MCRN studies closed to recruitment2012/13
WM-MCRN studies closed to recruitment2012/13
Burton WAITUHNS Sabre, SLEEPS, WAITBWH I2S2HEFT I2S2, TrophosSWBH MCRN074(Xalatan) I2S2
UHCW I2S2, WAIT
WM-MCRN studies closed to recruitment2012/13
MCRN revised feasibility process
Timelines aimed at attracting Industry to the UK
LRNs = ‘ADDED VALUE’
Feasibility underpins performance
� Speed of set-up and delivering to target
•Early feedback (Max 10 working days)
•Site intelligence (within 15 working days)
Form return 3 – 7 working days
•Site identification (within 15 working days)
Form return 8 – 12 working days
What impacts on HLOs for MCRN?Feasibility
�rare studies (<12 patients per year in the UK)
�paediatric study design
�timing of clinics and appropriateness of bringing patients in within 30 days for registries vs interventional trials
�percentage of industry studies in the portfolio
�competitive recruitment
�paediatric pharmacy
�engagement with CTUs
WM process has embraced the LRN role
Sensitivities!
Studies in set up 2012/13HLO4: Time for NHS permission
Studies in set up 2012/13HLO5: First patient recruited
Studies in set up 2013HLO4: Time for NHS permission
Studies in set up 2013HLO5: First patient recruited
2013
Closed Jan-June 2013 Closing in next 3 months
Open & recruiting studies 2013/14
2013/14 Data and Thoughts ……
Children's research portfolio
�Now and post-transition
� NIHR networks aim to facilitate, promote and engage in high quality research collaborations
�EUROPAIN:
�UK leading recruiter with 2,619 of 6,446 internationally
�MCRN success included opening the study across the UK and WM region, short set-up timeline, working with new teams, delivering research in PICUs, making research available to neonates